stockrow
Saturday 7 November 2026
Export ITRMF’s income statement to Excel — free account
Iterum Therapeutics PLC
ITRMF Healthcare Biotechnology
- Revenue
- +110.8%
- EPS
- +33.3%
- Free cash flow
- −179.2%
Quarter to September 2025, against a year earlier
0.00
0.00
NaN
Follow ITRMF
Alert me
| Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — |
Piotroski F-Score |
— | — | — | — | — | 2 | — | — | — |
P/S ratio |
— | — | — | — | — | 91.42 | 50.38 | 0.00 | — |
Altman Z-Score |
— | — | — | — | — | (26.27) | (2.47) | — | — |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | (63.33) | (1.37) | 2.90 | — |
P/Operating CF |
— | — | — | — | — | (2.84) | (1.84) | (0.22) | — |
Beneish M-Score |
— | — | — | — | — | 22.81 | (2.37) | — | — |
P/B ratio |
— | — | — | — | — | 0.00 | 0.61 | 0.11 | — |
Price to Tangible BV |
— | — | — | — | — | 0.00 | 0.61 | 0.11 | — |
EV/Sales |
— | — | — | — | — | 103.44 | (30.73) | 0.00 | — |
EV/EBITDA |
— | — | — | — | — | 0.00 | 0.35 | 0.00 | — |
EV/Operating CF |
— | — | — | — | — | (0.90) | 0.35 | 0.53 | — |
EV/FCF |
— | — | — | — | — | (0.90) | 0.35 | 0.52 | — |
Quick Ratio |
1.37 | 1.77 | 6.74 | 6.38 | 0.37 | 0.16 | 6.98 | 5.57 | 5.94 |
Current Ratio |
1.41 | 1.89 | 6.89 | 6.43 | 0.51 | 0.32 | 7.61 | 6.20 | 6.13 |
Net Debt/EBITDA |
0.24 | 0.29 | 1.93 | 3.97 | (0.68) | (0.08) | 0.93 | 1.33 | 1.86 |
Debt/Assets |
45.52% | 43.62% | 15.10% | 9.35% | 87.94% | 52.13% | 14.40% | 0.00% | 0.00% |
Debt/Equity |
(4.97) | (1.79) | 0.36 | 0.17 | (0.57) | (0.51) | 0.20 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
Operating CF/Net income |
1.08 | 1.03 | 0.42 | 0.17 | 1.05 | 0.79 | 0.98 | 1.04 | 0.84 |
Capex/Depreciation |
0.00 | 0.00 | (0.01) | (0.01) | 0.00 | (0.05) | (0.18) | (12.49) | — |
Interest Coverage |
(7.41) | (33.24) | (12.87) | (4.42) | (2.13) | (118.49) | — | (106.34) | — |
| 472.61% | (355.35%) | (113.59%) | 56,347.08% | 135.44% | (454.48%) | (138.69%) | (94.61%) | (43.29%) | |
| (69.93%) | (82.44%) | (56.12%) | (147.33%) | (177.67%) | (166.85%) | (106.56%) | (79.83%) | (36.55%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (4,201.00%) | (6,622.08%) | 0.00% |
Return on Tangible Assets |
(343.84%) | (316.36%) | (83.13%) | (130.03%) | 262.59% | 417.60% | (94.60%) | (77.81%) | (62.21%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10,959.86 | 302.84 | 365.72 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 245,335.14% | 7,899.54% | 5,019.49% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 30,497.30% | 1,010.47% | 878.74% | 0.00% |
Intangible Assets out of Total Assets |
0.44 | 0.00 | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5,872.97% | 148.45% | 77.17% | 0.00% |
Graham Net Nets |
— | — | — | — | — | (0.62) | 1.52 | 10.16 | — |
Graham Number |
— | — | — | — | — | 254.92 | 0.00 | 0.00 | — |
Earnings Yield |
— | — | — | — | — | (157.92%) | (1,338.04%) | (23.89%) | — |
Free Cash Flow Yield |
— | — | — | — | — | (125.36%) | (173.54%) | (1,692.84%) | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 1.49 | 44.17 | 0.00 |
Operating CF per Share |
(1.36) | (3.03) | (1.51) | (1.45) | (34.05) | (84.60) | (130.26) | (2,661.22) | (7,061.25) |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | (0.01) | (0.02) | (0.15) | (70.61) | 0.00 |
Free Cash Flow per Share |
(1.36) | (3.04) | (1.51) | (1.46) | (34.05) | (84.62) | (130.42) | (2,731.83) | (7,061.25) |
Cash per Share |
1.22 | 1.85 | 4.97 | 7.47 | 9.10 | 4.99 | 145.18 | 3,410.09 | 15,505.63 |
Shareholders Equity per Share |
(0.21) | (0.49) | 2.29 | 4.61 | (31.57) | (27.09) | 122.94 | 3,434.26 | 14,186.25 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.21) | (0.49) | 2.29 | 4.61 | (31.57) | (27.09) | 122.94 | 3,434.26 | 14,186.25 |
Free Cash Flow |
(26.77) | (39.34) | (18.53) | (15.90) | (54.54) | (81.95) | (75.98) | (31.42) | (11.30) |
Working Capital |
7.18 | 12.08 | 53.38 | 70.33 | (20.23) | (25.27) | 80.75 | 37.05 | 21.64 |
Capital Expenditures |
0.00 | (0.01) | (0.06) | (0.06) | (0.01) | (0.02) | (0.09) | (0.81) | — |
Net Current Asset Value |
(23.89) | (7.07) | 23.61 | 41.99 | (61.88) | (40.27) | 66.72 | 36.97 | 21.64 |
EV/EBIT |
— | — | — | — | — | 0.00 | 0.35 | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.65 | 0.10 | 1.60 | — |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
111.83 | 80.18 | 59.97 | 68.14 | 26.34 | 0.90 | 0.71 | 0.09 | — |
Cash ROIC |
(66.36%) | (135.76%) | (18.74%) | (11.35%) | 762.25% | 1,026.63% | (44.62%) | (39.91%) | (23.78%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 1.41 | 1.35 | 0.00 |
Accounts Payable Turnover |
0.10 | 0.00 | 0.99 | 2.48 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Days of Payables |
360.69 | 0.00 | 562.51 | 152.31 | 1,849.94 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Receivables |
0.04 | 0.17 | 0.75 | 1.04 | 0.99 | 0.92 | 0.62 | 0.38 | 0.38 |
Average Payables |
2.62 | 3.89 | 1.83 | 0.85 | 8.15 | 9.76 | 3.60 | 2.32 | 2.32 |
Average Assets |
35.43 | 46.55 | 79.17 | 62.15 | 29.27 | 61.81 | 72.31 | 36.84 | 36.84 |
Average Common Equity |
(5.24) | 10.80 | 39.12 | (0.16) | (38.40) | 22.69 | 55.56 | 31.08 | 31.11 |
Columns are period end dates